A Leading Developer of Allogeneic Cellular Therapies

Nohla Therapeutics is a clinical stage cell therapy company that’s redefining clinical outcomes for patients with critical diseases by providing a short-term hematopoietic bridge to immune repair and healthy blood production with long-term immunologic benefits.

Nohla’s proven platform generates universal, off-the shelf therapies that enable improved clinical outcomes across a number of disease indications, with an initial focus on high-risk hematological malignancies. Nohla’s lead candidate, dilanubicel (NLA101), is an expanded progenitor cell therapy that provides the functional support of bone marrow in response to each patient’s unique blood-production needs, without any requirement for HLA matching. The product has demonstrated the potential for robust efficacy in multiple clinical trials, while overcoming the broad safety and logistical risks of patient-customized cell therapies.

Management Team

Kathleen Fanning

President and Chief Executive Officer

Kathleen Fanning is the President and Chief Executive Officer of Nohla Therapeutics. Ms. Fanning has over 30 years of industry experience holding previous leadership roles in both public and private biopharmaceutical companies, most recently serving as Chief Operating Officer at VentiRx Pharmaceuticals. During her tenure at VentiRx, she led strategic planning activities and corporate and business development. She played an instrumental role in the strategic collaboration between VentiRx and Celgene Corporation. Prior to joining VentiRx, Ms. Fanning held senior leadership roles at Cell Therapeutics Inc., as Vice President of Acquisitions and Vice President of Sales and Marketing, with responsibilities that included building and managing the company’s first global sales and marketing organization. She also served as Senior Director of Sales and Marketing at CellPro, Inc. and spent 13 years at Zeneca Pharmaceuticals (now AstraZeneca), with increasing roles of responsibility including Director of Marketing for Oncology Products, where she led the successful U.S. launch of Arimidex®. Ms. Fanning received her B.A. in Zoology from Miami University in Oxford, Ohio.

Colleen Delaney, MD, MSc

Founder and Chief Medical Officer

Colleen Delaney is the Founder and Chief Medical Officer at Nohla Therapeutics. She is also an Associate Member and recipient of the Madeline Dabney Adams Endowed Chair of the Fred Hutch Clinical Research Division and an Associate Professor at the UW Department of Pediatrics, Division of Pediatric Hematology/Oncology. Colleen is a member on the Advisory Council on Blood Stem Cell Transplantation of the Health Resources and Services Administration. She also serves on the Boards of Directors of the American Society of Bone Marrow Transplant and the Cord Blood Association. In 2006, she established and became the Director of the Cord Blood Transplant Program at the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, which has grown to be one of the busiest such programs in the country and the coordinating center of several multicenter clinical trials. She is the sponsor-investigator of three Investigational New Drug FDA files and has been the Principal Investigator of nine ongoing and completed clinical trials and several ancillary studies.

Colleen is also the Principal Investigator of a research laboratory focused on the role of the Notch signaling pathway in hematopoietic stem cell regulation and ex-vivo expansion of umbilical cord blood stem and progenitor cells for clinical applications. Her group at Fred Hutchinson Cancer Research Center developed novel and clinically feasible methods for the ex vivo expansion of cord blood derived hematopoietic stem and progenitor cells in the presence of Notch ligands. This work was translated into a pilot study investigating the use of ex vivo expanded cord blood progenitors to augment conventional cord blood transplantation. She has since extended this work to investigate the potential of cryopreserved, non-HLA matched “off the shelf” ex vivo expanded cord blood progenitor cells to provide rapid but transient myeloid reconstitution in the setting of cord blood transplant and following dose-intensive chemotherapy.

Colleen received her MD from Harvard Medical School in 1996, and went on to complete a residency in Pediatrics at the University of California, San Francisco followed by a Fellowship in Pediatric Hematology/Oncology at Fred Hutchinson Cancer Research Center/University of Washington.

Gary Christianson, PE

Chief Operating Officer

Gary Christianson, PE, is Chief Operating Officer at Nohla Therapeutics. Mr. Christianson joins Nohla after serving as the Chief Operating Officer at Cascadian Therapeutics, Inc. since 2007. Cascadian Therapeutics was acquired by Seattle Genetics in March 2018. Prior to his role at Cascadian, Mr. Christianson served as the site director for GlaxoSmithKline’s Biologics Unit following its acquisition of Corixa Corp. From 1999 to 2005, Mr. Christianson held positions as vice president, technical operations and general manager overseeing manufacturing and commercial product development. Prior to Corixa, Mr. Christianson served for 12 years overseeing manufacturing and site operations at RIBI ImmunoChem Research, a biopharmaceutical company developing late-stage adjuvant technology. Mr. Christianson received a B.S. in mechanical engineering technology from Montana State University.

Jim Johnson

Chief Financial Officer

James (Jim) Johnson has served as Nohla Therapeutics’ Chief Financial Officer since January 2018. Prior to joining Nohla, he served as Chief Financial Officer of NanoString Technologies, a publicly-held provider of life science tools for translational research and molecular diagnostics, since 2012. During his tenure as CFO at NanoString, Mr. Johnson oversaw strategic and corporate finance activities from private stage through the company’s initial public offering and additional rounds of financing, marking the third IPO in his career as a CFO. Prior to NanoString, Mr. Johnson was Chief Financial Officer of Relypsa, Inc., a clinical-stage biopharmaceutical company, from 2011 to 2012. From 2001 to 2010, Mr. Johnson served most recently as Executive Vice President, Chief Financial Officer, Treasurer and Secretary of ZymoGenetics, Inc., a biopharmaceutical company acquired by Bristol-Myers Squibb in October 2010. Prior to Zymogenetics, Mr. Johnson served as Chief Financial Officer, Treasurer and Secretary of Targeted Genetics Corporation, a Seattle-based biotechnology company, from 1994 to February 2001. From 1988 to 1994, Mr. Johnson served as Vice President, Finance at Immunex Corporation, a Seattle-based biopharmaceutical company (acquired by Amgen in 2009). Mr. Johnson received a B.A. in Business Administration from the University of Washington.

Directors

Steven Gillis, PhD

Chairman

Steven Gillis has been a managing director at ARCH Venture Partners since 2005. Dr. Gillis was a founder and director of Corixa Corporation and served as the company’s Chief Executive Officer since inception and as its chairman since January of 1999. GlaxoSmithKline acquired Corixa Corporation in July of 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corporation. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis was interim Chief Executive officer of Immunex Corporation following its majority purchase by American Cyanamid Company. Dr. Gillis remained on the Board of Directors of Immunex until 1997. Immunex was acquired by Amgen in 2002. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978. He currently serves as a director or Chairman of multiple private and public biotechnology companies in the United States.

Brian Daniels, MD

Non-Executive Director

Brian Daniels, M.D. joined 5AM Ventures in 2014 as a Venture Partner. Prior to his joining, Dr. Daniels spent over two decades in clinical drug development including the last ten years as the leader of Development and Medical Affairs at Bristol-Myers Squibb. He directed the development of numerous innovative medicines that have contributed to improvements for patients across a range of serious diseases. These include: ORENCIA and NULOJIX in immunology/transplant, REYATAZ, DAKLINZA and BARACLUDE in virology, ONGLYZA, FARXIGA and MYALEPT in metabolics, ELIQUIS in CV and YERVOY, OPDIVO, SPRYCEL and IXEMPRA in oncology. Dr. Daniels is currently a Director of Spyryx Biosciences and served on the Scientific Advisory Board of Novira. Dr. Daniels received B.S. and M.S. degrees from MIT and his M.D. from Washington University in St. Louis. He trained in internal medicine at New York Hospital and Rheumatology/Immunology at UCSF.

Lawrence Gozlan

Non-Executive Director

Lawrence Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. With 15 years of experience in investing and banking, Lawrence has expertise in all areas of investment management and deep roots in the scientific and biotech communities. Prior to Scientia Lawrence was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over AU$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained corporate finance experience advising life science companies at Deloitte. Lawrence currently serves as a Director on the Board of Prana Biotechnology (NASDAQ: PRAN). He holds a Bachelor of Science with Honours in immunology from the University of Melbourne.

Michael Sistenich

Non-Executive Director

Michael Sistenich has over 18 years’ experience in senior leadership roles in the life sciences industry as an investor, advisor, and investment banker. Most recently, Michael served as Interim Chief Executive Officer of Nohla Therapeutics, Inc., during which time he successfully spearheaded its startup and guided its transformational Series A financing in November 2016. He was the Director and Head of life sciences investment banking at Bell Potter Securities from June 2014 until he joined Nohla. Prior to Bell Potter, he was the Founder and Senior Portfolio manager of the Meditor Cobra fund, a EUR 500mn Healthcare Hedge fund based in London. From 1997 to 2003, Michael served as Director and Global Head of Healthcare at DWS Investments, Deutsche Bank, overseeing EUR $6 billion of direct investments in the public and private markets. Michael holds an M.Sc in Biochemistry from the University of Oxford, UK.

Kathleen Fanning

President and Chief Executive Officer

Kathleen Fanning is the President and Chief Executive Officer of Nohla Therapeutics. Ms. Fanning has over 30 years of industry experience holding previous leadership roles in both public and private biopharmaceutical companies, most recently serving as Chief Operating Officer at VentiRx Pharmaceuticals. During her tenure at VentiRx, she led strategic planning activities and corporate and business development. She played an instrumental role in the strategic collaboration between VentiRx and Celgene Corporation. Prior to joining VentiRx, Ms. Fanning held senior leadership roles at Cell Therapeutics Inc., as Vice President of Acquisitions and Vice President of Sales and Marketing, with responsibilities that included building and managing the company’s first global sales and marketing organization. She also served as Senior Director of Sales and Marketing at CellPro, Inc. and spent 13 years at Zeneca Pharmaceuticals (now AstraZeneca), with increasing roles of responsibility including Director of Marketing for Oncology Products, where she led the successful U.S. launch of Arimidex®. Ms. Fanning received her B.A. in Zoology from Miami University in Oxford, Ohio.